Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis
Status:
Completed
Trial end date:
2020-01-22
Target enrollment:
Participant gender:
Summary
The antifungal efficacy and safety of Jublia® topical solution will be assessed through an
administration for 48 weeks to patients diagnosed with a mild or moderate onychomycosis due
to dermatophyte.